Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03668340 · ClinicalTrials.gov registry record · Phase 2

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

A Phase 2 study of Uterine Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
49
Enrollment target
1
Study location

NCT03668340 is a Phase 2 study of Uterine Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03668340, a Phase 2 study of Uterine Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

Conditions Studied

Uterine Cancer

Interventions

  • DRUG AZD1775

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2018-10-22
Est. Completion 2027-07-01
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03668340

The ClinicalTrials.gov registry entry for NCT03668340 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 270-participant average among 27 other Uterine Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uterine Cancer appearing as the primary indexed condition, and to 1 intervention - of which AZD1775 is the first listed.

NCT03668340 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03668340 about?

NCT03668340 is a clinical study titled "AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma". This research study is studying an investigational drug as a possible treatment for uterine cancer. The drug involved in this study is: -AZD1775

What is the current status of trial NCT03668340?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-10-22. Estimated completion is 2027-07-01.

What conditions does trial NCT03668340 study?

This clinical trial studies the following conditions: Uterine Cancer.

What interventions are being tested in trial NCT03668340?

The interventions under investigation include: AZD1775 (DRUG).

Who is sponsoring clinical trial NCT03668340?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03668340 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uterine Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.